Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal

[1]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[2]  C. Cheah,et al.  Rituximab for the treatment of follicular lymphoma. , 2013, Future oncology.

[3]  J. Kleijnen,et al.  Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal , 2013, PharmacoEconomics.

[4]  M. Stevenson,et al.  Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal , 2013, PharmacoEconomics.

[5]  S. Davis,et al.  Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal , 2013, PharmacoEconomics.

[6]  Y. Dundar,et al.  Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma , 2013, PharmacoEconomics.

[7]  M. Stevenson,et al.  Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal , 2013, PharmacoEconomics.

[8]  P. Tappenden,et al.  Bivalirudin for the Treatment of ST-Segment Elevation Myocardial Infarction: A NICE Single Technology Appraisal , 2013, PharmacoEconomics.

[9]  S. Palmer,et al.  Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer , 2013, PharmacoEconomics.

[10]  Dawn Craig,et al.  Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization , 2013, PharmacoEconomics.

[11]  S. Palmer,et al.  Dronedarone for the Treatment of Atrial Fibrillation , 2012, PharmacoEconomics.

[12]  G. Mowatt,et al.  Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura , 2012, PharmacoEconomics.

[13]  S. Whyte,et al.  Bevacizumab for Metastatic Colorectal Cancer , 2012, PharmacoEconomics.

[14]  J. Dipersio,et al.  Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I , 2012 .

[15]  T. Barbui,et al.  Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF) , 2012 .

[16]  C. Carroll,et al.  Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery , 2012, PharmacoEconomics.

[17]  I. Bruce,et al.  Golimumab for the Treatment of Psoriatic Arthritis , 2012, PharmacoEconomics.

[18]  D. Whalley,et al.  PCN95 Using a Condition-Specific Measure of Patient-Reported Outcomes to Derive Utilities in Myelofibrosis , 2012 .

[19]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[20]  S. Verstovsek,et al.  Ruxolitinib for the treatment of myelofibrosis: its clinical potential , 2012, Therapeutics and clinical risk management.

[21]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[22]  Y. Dundar,et al.  Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy , 2011, PharmacoEconomics.

[23]  P. Royle,et al.  Denosumab for the Prevention of Osteoporotic Fractures in Post-Menopausal Women , 2011, PharmacoEconomics.

[24]  M. Stevenson,et al.  Febuxostat for the Management of Hyperuricaemia in Patients with Gout , 2011, PharmacoEconomics.

[25]  M. Sculpher.  Single Technology Appraisal at the UK National Institute for Health and Clinical Excellence , 2010, PharmacoEconomics.

[26]  M. Sculpher,et al.  Alitretinoin for Severe Chronic Hand Eczema , 2012, PharmacoEconomics.

[27]  G. Mowatt,et al.  Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma , 2012, PharmacoEconomics.

[28]  R. Shaw,et al.  Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck , 2012, PharmacoEconomics.

[29]  王林,et al.  Orphanet , 2011 .

[30]  A. Tefferi,et al.  Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. , 2011, Mayo Clinic proceedings.

[31]  Sonali M. Smith,et al.  A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL , 2011 .

[32]  Z. Estrov,et al.  The MD Anderson Cancer Center (MDACC) Experience with Ruxolitinib, An Oral JAK1 and JAK2 Inhibitor, in Myelofibrosis: Long-Term Follow-up Outcomes of 107 Patients From a Phase I/II Study, , 2011 .

[33]  S. Verstovsek,et al.  Ruxolitinib for the treatment of myelofibrosis. , 2011, Drugs of today.

[34]  T. Barbui,et al.  Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Hutton,et al.  PHP56 DEMONSTRATING CLINICAL-EFFECTIVENESS USING INDIRECT AND MIXED TREATMENT COMPARISON ANALYSIS: A REVIEW OF MANUFACTURERS' SINGLE TECHNOLOGY APPRAISAL (STA) SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE) , 2011 .

[36]  S. Walker,et al.  Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years. , 2011, Health technology assessment.

[37]  I. Bruce,et al.  Golimumab for the treatment of psoriatic arthritis. , 2011, Health technology assessment.

[38]  P. Royle,et al.  Denosumab for the prevention of osteoporotic fractures in postmenopausal women. , 2011, Health technology assessment.

[39]  J. Kleijnen,et al.  Golimumab for the treatment of ankylosing spondylitis , 2011 .

[40]  T. Barbui,et al.  Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[42]  R. Rafia,et al.  Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. , 2010, Health technology assessment.

[43]  S. Carillo,et al.  Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study , 2009, Haematologica.

[44]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[45]  H. Kantarjian,et al.  A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF) , 2008 .

[46]  H. Deeg,et al.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.

[47]  H. Møller,et al.  The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East-England. , 2006 .

[48]  H. Møller,et al.  The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. , 2006, Haematologica.

[49]  R. McNally,et al.  Age and sex distributions of hematological malignancies in the U.K. , 1997, Hematological oncology.